SCHEMBL14006283

SCHEMBL14006283

CC(=O)N1CCCN(CCCCC(=O)Nc2ccc(Cl)cc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 10/20 0.62
TP53 P04637 1/20 0.59
CHRNA7 P36544 1/20 0.53
KCNH2 Q12809 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14006277 0.89 HTR1A (0.59) CACNA1GCHRNA7KCNH2
SCHEMBL14006221 0.87 CACNA1G (0.71) CACNA1GTP53CHRNA7
SCHEMBL14006298 0.86 HDAC3 (0.54) CHRNA7KCNH2
SCHEMBL14006149 0.86 CACNA1G (0.52) CACNA1GCHRNA7KCNH2
SCHEMBL14006278 0.85 CACNA1G (0.70) CACNA1GTP53CHRNA7
SCHEMBL14006219 0.85 CACNA1G (0.70) CACNA1GTP53CHRNA7
SCHEMBL14006291 0.84 EPHX2 (0.58) CHRNA7KCNH2
SCHEMBL2055592 0.82 CHRNA7 (0.59) CHRNA7KCNH2
SCHEMBL14006146 0.81 CHRNA7 (0.51) CHRNA7KCNH2
SCHEMBL14006150 0.81 CHRNA7 (0.53) CHRNA7KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275028-A1 Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof SIENA BIOTECH S.P.A. (IT) 2008-11-06 US disclosed
US-20080275028-A1 Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof SIENA BIOTECH S.P.A. (IT) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275028-A1 Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof CHRNA7, CHRNA5, CHRNA1 CACNA1G 324/4885TP53 3541/4885CHRNA7 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.